Log in
Enquire now
PsiOxus Therapeutics

PsiOxus Therapeutics

PsiOxus Therapeutics is an oncolytic Vaccines founded in 2010 by Kerry Fisher.

OverviewStructured DataIssuesContributors

Contents

psioxus.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Engineering
Engineering
Vaccine
Vaccine
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
Oncolytic virus
Oncolytic virus
Technology
Technology
Cancer
Cancer
...
Location
United Kingdom
United Kingdom
Oxford
Oxford
Oxfordshire
Oxfordshire
B2X
B2B
B2B
Founder
‌
Kerry Fisher
Pitchbook URL
pitchbook.com/profiles.../54774-19
Parent Organization
Imperial College London
Imperial College London
Number of Employees (Ranges)
11 – 500
Email Address
enquiries@psioxus.com
Investors
SR One
SR One
Imperial Innovations
Imperial Innovations
IP Group
IP Group
Bristol-Myers Squibb
Bristol-Myers Squibb
Revelation Partners
Revelation Partners
0
‌
Invesco Perpetual
Founded Date
2010
0
Total Funding Amount (USD)
22,000,000
Latest Funding Round Date
July 2012
Business Model
Commerce
Latest Funding Type
Series B
Series B
Country
United Kingdom
United Kingdom

Other attributes

Company Operating Status
Active
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like PsiOxus Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.